Women Face 45% Higher Mortality Risk: Cardiovascular disease (CVD) continues to be one of the leading causes of death worldwide, affecting both men and women. However, new research reveals that women face disproportionately higher risks when prescribed beta-blockers after a heart attack (myocardial infarction, MI), especially if they have preserved left ventricular ejection fraction (LVEF). According to findings published in the European Heart Journal, women treated with beta-blockers post-MI but without reduced heart pumping function face a 45% higher risk of adverse outcomes compared to men.
This groundbreaking evidence comes from the REBOOT trial, the largest randomized controlled trial examining beta-blocker use after acute MI. The analysis included over 8,400 patients, of whom 1,627 were women.
The REBOOT Trial and Its Findings
Study Overview
- Trial name: REBOOT (NCT03596385)
- Sample size: 8,438 patients
- Women participants: 1,627 (older, more comorbidities, fewer therapies than men)
- Follow-up period: Nearly 4 years
Outcomes
- Women on beta-blockers experienced 30 adverse events per 1,000 patients/year, compared to 21 per 1,000 for women not on beta-blockers.
- This translates into a 45% higher risk of death, MI, or heart failure hospitalization in women.
- For men, there was no significant difference in outcomes between those prescribed beta-blockers and those not.
- Risks were especially high in women with preserved LVEF and in those receiving higher doses of beta-blockers.
Why Women Are at Higher Risk
- Hormonal differences: Estrogen and other sex hormones influence heart function, platelet activity, and drug metabolism.
- Comorbidity burden: Women in the trial were older and had more chronic health conditions, increasing vulnerability.
- Pharmacological sensitivity: Evidence shows women often have stronger or adverse drug reactions, with CVD drugs posing a 1.5 to 1.7 times higher risk of side effects.
- Clinical trial gaps: Historically, women are underrepresented in cardiovascular trials, leading to male-centered treatment guidelines.
Also read: Realme 15T 5G Announced: Redmi 15 Rival with 7,000mAh Battery Launching on September 2
Women Face 45% Higher Mortality Risk FAQ’s
1. Why do beta-blockers increase mortality risk in women after a heart attack?
Women metabolize and respond to drugs differently due to hormonal and physiological differences. In the REBOOT trial, beta-blockers were linked to a higher risk of death, MI, and heart failure hospitalization in women, especially those with preserved LVEF.
2. Are beta-blockers safe for men after myocardial infarction?
Yes. The trial showed no significant increase in adverse outcomes for men taking beta-blockers after MI.
3. Should women stop taking beta-blockers after a heart attack?
No. Patients should never stop prescribed medications without consulting their doctor. The study does not call for eliminating beta-blockers but rather for cautious, personalized use in women, especially those with preserved LVEF or on higher doses.
4. What alternatives exist for women at risk from beta-blockers?
Treatment depends on individual health profiles. Alternatives may include ACE inhibitors, ARBs, statins, lifestyle modifications, and personalized rehabilitation plans.